Guardion Health Sciences, Inc.

GHSI

US40145Q5009

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 09:55:26 2024-05-22 am EDT			5-day change	1st Jan Change
9.215 ^USD	-0.54%		+4.54%	+69.14%

Mar. 29	Guardion Health Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 05	North American Morning Briefing : Hopes of March -2-	DJ

Guardion Health Sciences, Inc. Provides Revenue Guidance for the Third Quarter of Fiscal 2019

October 28, 2019

Guardion Health Sciences, Inc. provided revenue guidance for the third quarter of fiscal 2019. The company estimates for the third fiscal quarter, total revenue will be in the range of approximately $150,000 to $160,000.

Latest news about Guardion Health Sciences, Inc.

Guardion Health Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
North American Morning Briefing : Hopes of March -2-	Feb. 05	DJ
Maxim Downgrades Guardion Health Sciences to Hold From Buy	Feb. 02	MT
Top Midday Gainers	Jan. 31	MT
Alphabet Earnings, Upcoming Fed Rate Decision Drive Mixed Premarket Action for US Equity Futures	Jan. 31	MT
Top Premarket Gainers	Jan. 31	MT
Doctor's Best, Inc. agreed to acquire Activ Nutritional, LLC. from Guardion Health Sciences, Inc. for $17.2 million.	Jan. 29	CI
Guardion Health Sciences Continues its Strategic Review Process	Nov. 13	CI
Guardion Health Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Guardion Health Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Guardion Health Sciences, Inc. Announces Executive Changes	23-07-31	CI
US Stock Futures Trend Higher Ahead of Consumer Sentiment Report	23-06-30	MT
Top Premarket Decliners	23-06-30	MT
Guardion Health Sciences, Inc. Announces Executive Changes	23-05-30	CI
Guardion Health Sciences, Inc. Announces CEO Changes	23-05-30	CI
Guardion Health Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Guardion Health Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Guardion Health Sciences Hires Alantra, LLC as Financial Advisor to Explore Strategic Alternatives to Maximize Stockholder Value	23-03-06	CI
Guardion Health Sciences Regains Compliance With Nasdaq Listing Rules	23-01-25	MT
Insider Buy: Guardion Health Sciences	23-01-11	MT
Guardion Health Sciences, Inc. announced that it expects to receive $4.75 million in funding	22-11-28	CI
Guardion Health Sciences Engages Financial Advisor to Conduct a Strategic Review Process	22-11-14	CI
Guardion Health Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Guardion Health Sciences, Inc. Announces Clinical Results Indicating that Viactiv® Omega Boost™ Gel Bites Increase Omega-3 Levels in Just 4 weeks	22-10-06	CI
Guardion Health Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI

Chart Guardion Health Sciences, Inc.

Duration

Period

More charts

Company Profile

Guardion Health Sciences, Inc. is a clinical nutrition company. The Company offers a portfolio of science-based, clinically supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients. The Company, through Activ Nutritional, LLC (Activ), owns the Viactiv line of supplements for bone health and other applications. The Viactiv line of supplements contains several flavored nutritional supplement products, but the milk chocolate and caramel flavored calcium chews constitute the main product category. It also sells Lumega-Z, its medical food product that has a formula designed to replenish and restore the macular protective pigment, simultaneously delivering critical and essential nutrients to the eye. The Company's GlaucoCetin is a dietary supplement in a capsule form designed specifically to provide nutrients to support mitochondrial function with additional antioxidants to help reduce oxidative stress.

Sector

Pharmaceuticals

Calendar

2024-05-23 - Extraordinary Shareholders Meeting - Restructuring Vote

More about the company

Income Statement Evolution

More financial data

Ratings for Guardion Health Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

9.265

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GUARDION HEALTH SCIENCES, INC.	+69.14%	11.9M
ELI LILLY AND COMPANY	+37.24%	723B
NOVO NORDISK A/S	+31.00%	598B
JOHNSON & JOHNSON	-2.92%	364B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+4.08%	288B
ASTRAZENECA PLC	+16.13%	244B
NOVARTIS AG	+9.82%	210B
ROCHE HOLDING AG	-5.15%	208B
AMGEN INC.	+8.78%	169B

Other Pharmaceuticals